Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Average Rating of “Hold” from Brokerages

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) has earned a consensus rating of “Hold” from the nine ratings firms that are presently covering the company, MarketBeat.com reports. Five analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $8.24.

A number of equities analysts have recently commented on ZNTL shares. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Zentalis Pharmaceuticals in a report on Thursday, March 27th. UBS Group decreased their price target on Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating on the stock in a research note on Tuesday, January 28th. Wells Fargo & Company cut their target price on shares of Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating on the stock in a report on Thursday, January 30th. Finally, Wedbush reiterated a “neutral” rating and set a $4.00 price target on shares of Zentalis Pharmaceuticals in a report on Friday, March 28th.

Zentalis Pharmaceuticals Stock Performance

Shares of ZNTL stock opened at $1.45 on Monday. The firm’s 50 day moving average is $1.57 and its 200 day moving average is $2.45. The stock has a market capitalization of $104.13 million, a P/E ratio of -0.58 and a beta of 1.80. Zentalis Pharmaceuticals has a 12 month low of $1.01 and a 12 month high of $13.24.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last posted its earnings results on Wednesday, March 26th. The company reported ($0.66) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.09. The company had revenue of $26.90 million for the quarter. On average, equities analysts predict that Zentalis Pharmaceuticals will post -2.42 EPS for the current year.

Insider Buying and Selling at Zentalis Pharmaceuticals

In other news, Director Scott Dunseth Myers bought 21,000 shares of the firm’s stock in a transaction dated Wednesday, April 30th. The stock was purchased at an average price of $1.40 per share, with a total value of $29,400.00. Following the transaction, the director now owns 281,192 shares of the company’s stock, valued at approximately $393,668.80. The trade was a 8.07 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Ingmar Bruns purchased 20,000 shares of the company’s stock in a transaction that occurred on Thursday, February 6th. The shares were purchased at an average price of $2.28 per share, for a total transaction of $45,600.00. Following the completion of the transaction, the insider now directly owns 36,629 shares of the company’s stock, valued at $83,514.12. This represents a 120.27 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 3.60% of the company’s stock.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in ZNTL. Integral Health Asset Management LLC bought a new position in Zentalis Pharmaceuticals during the 4th quarter valued at approximately $3,182,000. Almitas Capital LLC lifted its stake in shares of Zentalis Pharmaceuticals by 69.3% in the fourth quarter. Almitas Capital LLC now owns 1,626,896 shares of the company’s stock worth $4,929,000 after buying an additional 665,968 shares in the last quarter. Peapod Lane Capital LLC bought a new stake in shares of Zentalis Pharmaceuticals during the first quarter valued at approximately $888,000. Boxer Capital Management LLC purchased a new position in Zentalis Pharmaceuticals in the 4th quarter worth approximately $1,364,000. Finally, JPMorgan Chase & Co. lifted its position in Zentalis Pharmaceuticals by 75.7% in the 4th quarter. JPMorgan Chase & Co. now owns 859,710 shares of the company’s stock valued at $2,605,000 after acquiring an additional 370,511 shares in the last quarter.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.